Vertex Pharmaceuticals Inc (VRTX)
465.70
-18.26
(-3.77%)
USD |
NASDAQ |
Nov 15, 16:00
466.00
+0.30
(+0.06%)
After-Hours: 20:00
Vertex Pharmaceuticals Research and Development Expense (TTM): 3.456B for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 3.456B |
| June 30, 2024 | 3.390B |
| March 31, 2024 | 3.209B |
| December 31, 2023 | 3.163B |
| September 30, 2023 | 3.032B |
| June 30, 2023 | 2.867B |
| March 31, 2023 | 2.682B |
| December 31, 2022 | 2.540B |
| September 30, 2022 | 2.414B |
| June 30, 2022 | 2.236B |
| March 31, 2022 | 2.085B |
| December 31, 2021 | 1.940B |
| September 30, 2021 | 1.838B |
| June 30, 2021 | 1.865B |
| March 31, 2021 | 1.837B |
| December 31, 2020 | 1.830B |
| September 30, 2020 | 1.843B |
| June 30, 2020 | 1.905B |
| March 31, 2020 | 1.864B |
| December 31, 2019 | 1.754B |
| September 30, 2019 | 1.712B |
| June 30, 2019 | 1.487B |
| March 31, 2019 | 1.445B |
| December 31, 2018 | 1.416B |
| September 30, 2018 | 1.285B |
| Date | Value |
|---|---|
| June 30, 2018 | 1.410B |
| March 31, 2018 | 1.362B |
| December 31, 2017 | 1.325B |
| September 30, 2017 | 1.266B |
| June 30, 2017 | 1.084B |
| March 31, 2017 | 1.065B |
| December 31, 2016 | 1.048B |
| September 30, 2016 | 1.109B |
| June 30, 2016 | 1.083B |
| March 31, 2016 | 1.036B |
| December 31, 2015 | 995.92M |
| September 30, 2015 | 887.20M |
| June 30, 2015 | 831.86M |
| March 31, 2015 | 832.49M |
| December 31, 2014 | 855.51M |
| September 30, 2014 | 892.50M |
| June 30, 2014 | 921.01M |
| March 31, 2014 | 918.98M |
| December 31, 2013 | 898.45M |
| September 30, 2013 | 832.82M |
| June 30, 2013 | 813.54M |
| March 31, 2013 | 787.63M |
| December 31, 2012 | 765.90M |
| September 30, 2012 | 779.51M |
| June 30, 2012 | 768.40M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
1.754B
Minimum
Dec 2019
3.456B
Maximum
Sep 2024
2.388B
Average
2.160B
Median
Research and Development Expense (TTM) Benchmarks
| Gilead Sciences Inc | 8.104B |
| Eli Lilly and Co | 10.53B |
| Bristol-Myers Squibb Co | 10.45B |
| Moderna Inc | 4.827B |
| Pfizer Inc | 10.60B |